References
Beers MH, ed. Neuromuscular junction disorders. In Merck Manual-Second Home Edition.
Berrouschot J, Baumann I, et al. Therapy of myasthenic crisis. Crit Care Med. 1997 Jul;25(7):1228–35.
Carandina-Maffeis R, Nucci A, et al. Plasmapheresis in the treatment
of myasthenia gravis: Retrospective study of 26 patients. Arq
Neuropsiquiatr. 2004 Jun;62(2B):391–5.
Cheng YS, Lu CZ, et al. 128 cases of myasthenia gravis treated with huperzine A. New Drugs Clin Remedies. 1986;5:197–9.
Chiu HC, Chen WH, et al. The six year experience of plasmapheresis
in patients with myasthenia gravis. Ther Apher. 2000 Aug;4(4):291–5.
Cohen MS, Younger D. Aspects of the natural history of myasthenia gravis: Crisis and death. Ann N Y Acad Sci. 1981;377:670–7.
Drachman DB. Myasthenia gravis. N Eng J Med. 1994;330(25):1797–810.
Duan RS, Link H, et al. Dehydroepiandrosterone therapy ameliorates
experimental autoimmune myasthenia gravis in Lewis rats. J Clin
Immunol. 2003 Mar;23(2):100–6.
Foulks CJ. Myasthenia gravis presenting as laryngeal stridor after
exposure to chlorine gas. South Med J. 1981 Nov;74(11):1423–4.
Gelenberg AJ, Doller-Wojcik JC, et al. Choline and lecithin in the
treatment of tardive dyskinesia: Preliminary results from a pilot
study. Am J Psychiatry. 1979 Jun;136(6):772–6.
Gronseth GS, Barohn RJ. Practice parameter: Thymectomy for
autoimmune myasthenia gravis (an evidence-based review). Neurology.
2000;55(7):15.
Hoch W, McConville J, et al. Auto-antibodies to the receptor
tyrosine kinase MuSK in patients with myasthenia gravis without
acetylcholine receptor antibodies. Nat Med. 2001 Mar;7(3):365–8.
Kasper DL, Braunwald E, et al. Harrison's Principles of Internal
Medicine. 16th ed. New York: McGraw-Hill Medical Publishing Division;
2005.
Leker RR, Karni A, et al. Exacerbation of myasthenia gravis during the menstrual period. J Neurol Sci. 1998;156(1):107–11.
Lin JH, Hu GY, et al. Comparison between huperzine A, tacrine, and
E2020 on cholinergic transmission at mouse neuromuscular junction in
vitro. Zhongguo Yao Li Xue Bao. 1997 Jan;18(1):6–10.
Mocchegiani E, Giacconi R, et al. Different age-related effects of
thymectomy in myasthenia gravis: Role of thymoma, zinc, thymulin, IL-2
and IL-6. Mech Ageing Dev. 2000 Aug 15;117(1–3):79–91.
Onodera H. The role of the thymus in the pathogenesis of myasthenia gravis. Tohoku J Exp Med. 2005 Oct;207(2):87–98. Review.
Phillips LH. The epidemiology of myasthenia gravis. Neurologic Clinics of North Am. 1994;12(2):263–71.
Poea-Guyon S, Christadoss P, et al. Effects of cytokines on
acetylcholine receptor expression: Implications for myasthenia gravis.
J Immunol. 2005 May 15;174(10):5941–9.
Reddi K, Henderson B, et al. Interleukin 6 production by
lipopolysaccharide-stimulated human fibroblasts is potently inhibited
by naphthoquinone (vitamin K) compounds. Cytokine. 1995 Apr;7(3):287–90.
Roberts PF, Venuta F, et al. Thymectomy in the treatment of ocular
myasthenia gravis. J Thoracic and Cardiovasc Surg. 2001;122:562–8.
Ronager J, Ravnborg M, et al. Immunoglobulin treatment versus plasma
exchange in patients with chronic moderate to severe myasthenia gravis.
Artif Organs. 2001 Dec;25(12):967–73.
Roxanis I, Micklem K, et al. Thymic myoid cells and germinal center
formation in myasthenia gravis: Possible roles in pathogenesis. J
Neuroimmunol. 2002 Apr;125(1–2):185–97.
Shiono H, Roxanis I, et al. Scenarios for autoimmunization of T and
B cells in myasthenia gravis. Ann N Y Acad Sci. 2003 Sep;998:237–56.
Stout JR, Eckerson JM, et al. Effects of resistance exercise and
creatine supplementation on myasthenia gravis: A case study. Med Sci
Sports Exerc. 2001 Jun;33(6):869–72.
Thomas CE, Mayer SA, et al. Myasthenic crisis: Clinical features,
mortality, complications, and risk factors for prolonged intubation.
Neurology. 1997 May;48(5):1253–60.
van Doorn PA, Brand A, et al. High-dose intravenous immunoglobulin
treatment in chronic inflammatory demyelinating polyneuropathy: A
double-blind, placebo-controlled, crossover study. Neurology. 1990
Feb;40(2):209–12.
Waldbott GL. The preskeletal phase of chronic fluoride intoxication. Fluoride. 1998;31(1):13–20.
Wang R, Yan H, et al. Progress in studies of huperzine A, a natural
cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol
Sin. 2006 Jan;27(1):1–26.
Wegner B, Ahmed I. Intravenous immunoglobulin monotherapy in
long-term treatment of myasthenia gravis. Clin Neurol Neurosurg. 2002
Dec;105(1):3–8.
Wurtman RJ, Growdon JH. Dietary enhancement of CNS neurotransmitters. Hosp Pract. 1978 Mar;13(3):71–7.
Print
PDF
Email
View Health Concern
